AllSci News
Mount Sinai Health System adopts Sophia Genetics SOPHiA DDM platform for cancer genomics sequencing
Mount Sinai Health System has adopted the SOPHiA DDM platform from Sophia Genetics (NASDAQ: SOPH), a cloud-native AI genomics company, to support...
Kestrel's pan-KRAS inhibitor swoops into Phase I for advanced solid tumors
Kestrel Therapeutics, a Watertown, Massachusetts-based biotechnology company, has opened a first-in-human Phase I clinical trial for KST-6051, an oral...
Trevi Therapeutics raises USD 150 million in underwritten public offering of common stock
Trevi Therapeutics (NASDAQ: TRVI), a New Haven, Connecticut-based clinical-stage biopharmaceutical company focused on chronic cough, has priced an...
University of Delaware receives USD 1.36m NIH grant for ephrin signaling research
The University of Delaware has received a USD 1.36 million R01 research grant from the National Institute of General Medical Sciences to investigate how a...
University of North Carolina receives USD 1.08m NHLBI R35 award for platelet biology research
The University of North Carolina at Chapel Hill has received an NHLBI R35 award through NIH research grants totaling USD 1,081,420 for the current budget...
University of Miami receives USD 3.15m NIH grant for neonatal genome sequencing antisense therapy
The University of Miami School of Medicine has received a USD 3.15 million NIH R01 grant from the National Human Genome Research Institute to build a...
Columbia University receives USD 3.2m NIH grant for RNA-binding protein mapping methods
Columbia University has received a USD 3.2 million R01 grant from the National Human Genome Research Institute to develop new computational and experimental...
METiS TechBio's enters MTS109 into Phase I for refractory autoimmune disease
Shanghai Changzheng Hospital has opened enrollment in the first-in-human MTS109 clinical trial (NCT07526350), testing an mRNA-encoded, lipid...
Shanghai Henlius's HLX3902 trispecific antibody enters Phase I trial for advanced solid tumours
Shanghai Henlius Biotech, the HKEX-listed Chinese biopharmaceutical company, has registered a first-in-human Phase I clinical trial for HLX3902, a...
Jade Biosciences' anti-BAFF-R antibody entering Phase I for rheumatoid arthritis
Jade Biosciences, a NASDAQ-listed clinical-stage company (ticker: JBIO), has registered a first-in-human Phase I trial of JADE201, an afucosylated,...
Freya Bio's live biotherapeutic shows promise in Phase I trial for IVF embryo implantation failure
Freya Biosciences reported Phase I data for FB301, a defined multi-strain Lactobacillus live biotherapeutic, showing that the vaginally administered product...
Cochrane review of anti-amyloid Alzheimer’s drugs draws researcher pushback over pooled analysis
A Cochrane review published this week suggested that anti-amyloid beta monoclonal antibodies produce “trivial effects” on cognitive function and dementia severity while…
FDA delays review of Savara's molgramostim inhalation solution for autoimmune PAP to November
The US FDA has extended its review period for the Biologics License Application (BLA) submitted by Savara Inc. for molgramostim inhalation solution...
Eli Lilly's orforglipron set for approval filing in diabetes after positive Phase III results
Eli Lilly (NYSE: LLY) reported that orforglipron (Foundayo) met its primary cardiovascular safety endpoint in the Phase III ACHIEVE-4 trial, demonstrating...
National Heart, Lung, and Blood Institute backs LSU Health Sciences Center for microRNA hypertension research
The National Heart, Lung, and Blood Institute has awarded USD 1,008,719 to LSU Health Sciences Center under the R35 Outstanding Investigator Award mechanism...
The AllSci Brief
Free, systematic R&D and deal news. Daily.